The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Dyspepsi och reflux. Systematisk litteraturöversikt från SBU

Dyspepsia and reflux. Systematic literature review from SBU

På svenska

Author

  • Christer Staël von Holstein
  • Anders Norlund

Summary, in English

SBU performed a systematic review concerning dyspepsia and gastroesophageal reflux disease (GERD). The review included the perspective of managing patients in primary care. Dyspepsia is a common condition but varies from one geographic area to another. Despite presenting symptoms of dyspepsia, a majority of patients may not have an ulcer diagnosis (non-ulcer dyspepsia [NUD]). For undiagnosed GERD and diagnosed erosive GERD, proton pump inhibitors (PPIs) provide better relief of symptoms than histamine-H2 antagonists. When it comes to long-term treatment of erosive GERD, continued use of PPIs leads to better patient outcomes than PPIs on demand. PPIs are safe for long-term treatment and indicated even for young patients. Adverse effects are rare. Eradication of H. pylori reduces the risk of duodenal ulcer and ventricular ulcer. Eradication of H. pylori is more effective than acid suppression alone for preventing a new episode of bleeding. Eradication of H. pylori for patients with NUD may provide minor relief of symptoms. But because the majority of patients with NUD are not infected with H. pylori, the treatment will have no effect on them. PPIs may provide some relief of NUD symptoms, but studies that analyzed the effectiveness of PPIs for NUD symptoms also included patients with GERD. As a result, it is difficult to draw any conclusions in that regard. Patients with Barrett's esophagus are at increased risk of developing adenocarcinoma of the esophagus. However, published studies offer no evidence that screening or surveillance will detect cancer at an early stage. There is a need for independent dyspepsia research, including health economic studies.

Department/s

Publishing year

2007

Language

Swedish

Pages

7-1414

Publication/Series

Läkartidningen

Volume

104

Issue

18

Document type

Journal article

Publisher

Swedish Medical Association

Topic

  • Surgery

Keywords

  • Adenocarcinoma: etiology
  • Adult
  • Antacids: therapeutic use
  • Barrett Esophagus: complications
  • Barrett Esophagus: diagnosis
  • Barrett Esophagus: drug therapy
  • Dyspepsia: diagnosis
  • Dyspepsia: drug therapy
  • Esophageal Neoplasms: etiology
  • Esophagitis: complications
  • Esophagitis: drug therapy
  • Female
  • Gastroesophageal Reflux: complications
  • Gastroesophageal Reflux: diagnosis
  • Gastroesophageal Reflux: drug therapy
  • Helicobacter Infections: complications
  • Proton Pumps: antagonists & inhibitors
  • Peptic Ulcer: microbiology
  • Peptic Ulcer: drug therapy
  • Male
  • Humans
  • Helicobacter Infections: drug therapy
  • Helicobacter pylori
  • Risk Factors

Status

Published

ISBN/ISSN/Other

  • ISSN: 0023-7205